These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 2180212

  • 1. [Pharmacotherapy of hyperlipoproteinemias: indications, mechanisms of action, effectiveness and side effects].
    Schernthaner G, Woschnagg H.
    Wien Med Wochenschr; 1990 Feb 15; 140(3):64-75. PubMed ID: 2180212
    [Abstract] [Full Text] [Related]

  • 2. [Which antilipemic agent when?].
    Schwandt P.
    Internist (Berl); 1989 Sep 15; 30(9):625. PubMed ID: 2807786
    [No Abstract] [Full Text] [Related]

  • 3. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Sep 15; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 4. [Metabolism kinetic characterization of hypertriglyceridemias in drug therapy variations].
    Schulze J, Julius U, Leonhardt W, Haller H.
    Z Gesamte Inn Med; 1987 Sep 15; 42(18):506-11. PubMed ID: 3687141
    [Abstract] [Full Text] [Related]

  • 5. [Dyslipoproteinemia of diabetes: fibrates or statins?].
    Moulin P.
    Diabetes Metab; 1999 Sep 15; 25(3):270-4. PubMed ID: 10499198
    [No Abstract] [Full Text] [Related]

  • 6. Identification of the patient at risk in the physician's office and drug management of dyslipoproteinemia.
    Davignon J, Xhignesse M, Roederer G.
    Can J Cardiol; 1988 Jul 15; 4 Suppl A():36A-47A. PubMed ID: 3052739
    [Abstract] [Full Text] [Related]

  • 7. Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
    Paragh G, Balogh Z, Boda J, Kovács P, Kárpáti L, Szabó J, Leövey A.
    Acta Biol Hung; 1997 Jul 15; 48(3):359-67. PubMed ID: 9406614
    [Abstract] [Full Text] [Related]

  • 8. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K, Djaja S, Richter E.
    Ther Ggw; 1982 May 15; 121(5):301-11. PubMed ID: 6953613
    [No Abstract] [Full Text] [Related]

  • 9. Dyslipidemia and atherosclerosis. A forecast of pharmaceutical approaches.
    Gotto AM.
    Circulation; 1993 Apr 15; 87(4 Suppl):III54-9. PubMed ID: 8462181
    [Abstract] [Full Text] [Related]

  • 10. [Intestinal cholesterol absorption: a pharmacological target for lowering of plasma cholesterol].
    Catapano AL, Catapano L, Fellin R.
    Ital Heart J Suppl; 2004 Oct 15; 5(10):779-84. PubMed ID: 15615349
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
    Tomei R, Rossi L, Carbonieri E, Franceschini L, Cemin C, Ghebremariam-Tesfau K, Zardini P.
    Cardiologia; 1993 Dec 15; 38(12):773-8. PubMed ID: 8200011
    [Abstract] [Full Text] [Related]

  • 12. [Medical recommendations and references about hypolipidemic drugs. ANDEM (National Agency for the Development of Medical Evaluation].
    J Mal Vasc; 1997 Oct 15; 22(4):249-64. PubMed ID: 9411011
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS.
    Am J Ther; 2008 Oct 15; 15(2):102-7. PubMed ID: 18356628
    [Abstract] [Full Text] [Related]

  • 14. Lipid disturbances in chronic renal failure--patomechanisms and treatment.
    Rutkowski B, Chmielewski M.
    Rocz Akad Med Bialymst; 2004 Oct 15; 49():139-44. PubMed ID: 15631330
    [Abstract] [Full Text] [Related]

  • 15. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F, Ok E, Duman S, Kürsad S, Unsal A, Alev M, Atabay G, Basçi A.
    Adv Perit Dial; 1996 Oct 15; 12():261-5. PubMed ID: 8865916
    [Abstract] [Full Text] [Related]

  • 16. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T, Sakuma K, Nosaka S.
    J Cardiovasc Pharmacol Ther; 2006 Jun 15; 11(2):142-8. PubMed ID: 16891292
    [Abstract] [Full Text] [Related]

  • 17. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC.
    Pharmacotherapy; 1995 Jun 15; 15(3):317-37. PubMed ID: 7667166
    [Abstract] [Full Text] [Related]

  • 18. Incides of lipid peroxidation in patients with hypercholesterolemia and hypertriglyceridemia.
    Domagała B, Hartwich J, Szczeklik A.
    Wien Klin Wochenschr; 1989 Jun 09; 101(12):425-8. PubMed ID: 2750170
    [Abstract] [Full Text] [Related]

  • 19. [Basic principles of drug therapy of hyperlipoproteinemia].
    Romics L.
    Orv Hetil; 1988 Nov 06; 129(45):2391-9. PubMed ID: 3054710
    [No Abstract] [Full Text] [Related]

  • 20. Managing hyperlipidaemia.
    Nestel PJ.
    Med J Aust; 1988 Jan 04; 148(1):29-31. PubMed ID: 3336296
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.